Evidence map›Paper›PMID 42540435›Full record

ArticleOphthalmology science2026

Consensus Guidance for Screening, Classification, and Treatment of Retinopathy Associated with Incontinentia Pigmenti.

Jade Y Moon, Becky Abbott, Audina Berrocal, Connie Chen, Xi Chen, Philip Ferrone, Mary Fete, Morton F Goldberg, Dorothy K Grange, Ian Han and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jade Y MoonDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota.
Becky AbbottNational Foundation of Ectodermal Dysplasias, Fairview Heights, Illinois.
Audina BerrocalBascom Palmer Eye Institute, University of Miami, Miami, Florida.
Connie ChenDepartment of Ophthalmology, Virginia Mason Medical Center, Seattle, Washington.
Xi ChenDepartment of Ophthalmology, Duke Eye Center, Durham, North Carolina.
Philip FerroneDepartment of Ophthalmology, Vitreoretinal Consultants of New York, Great Neck, New York.
Mary FeteNational Foundation of Ectodermal Dysplasias, Fairview Heights, Illinois.
Morton F GoldbergDepartment of Ophthalmology, Wilmer Eye Institute at Johns Hopkins University School of Medicine, Baltimore, Maryland.
Dorothy K GrangeDivision of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri.
Ian HanDepartment of Ophthalmology, University of Iowa, Iowa City, Iowa.
M Elizabeth HartnettByers Eye Institute, Stanford University, Palo Alto, California.
Robert H HendersonGreat Ormond Street Hospital, London, United Kingdom.
Eric NudlemanShiley Eye Institute, University of California San Diego, San Diego, La Jolla, California.
Sengul OzdekDepartment of Ophthalmology, Gazi University School of Medicine, Ankara, Turkey.
Richard N SatherDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota.
Nicole SomaniDepartment of Ophthalmology, University of Iowa, Iowa City, Iowa.
Reid WilsonCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Sandra R MontezumaDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota.
J Peter CampbellCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Incontinentia pigmenti (IP) is a rare genetic condition that can lead to blindness. Clinical practice for screening for the ocular complications of IP is variable. Current literature lacks consensus for the screening, classification, and treatment of IP-related eye disease despite substantial risk of retinal detachment (RD) and blindness. This report summarizes the state of knowledge and establishes expert guidance for screening, classification, and treatment of IP-related eye disease from the International Conference on Incontinentia Pigmenti (ICIP) sponsored by the National Foundation for Ectodermal Dysplasias in February 2025. Design: Literature review. Subjects: Images from authors' patients with a diagnosis of IP were included in this study. Methods: We review the current literature on screening and treatment of retinal complications of IP and provide guidance on disease screening, classification, and management from the ICIP in 2025. Main Outcome Measures: Screening, treatment, and surveillance options were reviewed. Results: The ICIP established guidance to support parents and ophthalmologists in appropriate screening and treatment of infants diagnosed with IP. Due to the high prevalence of retinal involvement in IP, infants diagnosed with IP should receive an early, comprehensive retinal examination, ideally with widefield fluorescein angiography. Like treatment considerations for other pediatric diseases with retinal ischemia, treatment concentrates acutely on regression of neovascularization and strategies to reduce incidence of RDs later in life. Conclusions: Incontinentia pigmenti is a rare but complex multisystem disorder with the potential for serious retinal complications. Careful ophthalmic screening and surveillance are crucial to optimize patients' visual outcomes. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

BlindnessIncontinentia pigmentiPediatric retinaScreening guidelinesVascular retinopathy

Identifiers

PMID42540435
PMCPMC13425831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.